title: Antihistamine-resistant  urticaria factitia  successfully treated  with anti-immunoglobulin  E therapy.
authors.affiliation: Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Krause
authors.forename: E
authors.initials: E
authors.lastname: Ardelean
authors.forename: B
authors.initials: B
authors.lastname: Kessler
authors.forename: M
authors.initials: M
authors.lastname: Magerl
authors.forename: M
authors.initials: M
authors.lastname: Metz
authors.forename: F
authors.initials: F
authors.lastname: Siebenhaar
authors.forename: K
authors.initials: K
authors.lastname: Weller
authors.forename: M
authors.initials: M
authors.lastname: Worm
authors.forename: T
authors.initials: T
authors.lastname: Zuberbier
authors.forename: M
authors.initials: M
authors.lastname: Maurer
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D007073:Immunoglobulin E; D008875:Middle Aged; D000069444:Omalizumab; D014581:Urticaria / Q000188:drug therapy*
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006633:Histamine Antagonists; D000069444:Omalizumab; D007073:Immunoglobulin E